[用于治疗缺血再灌注的磷酸二酯酶5抑制剂的更新]
[Update of PDE5 inhibitors for the treatment of ischemia-reperfusion].
作者信息
Hu Yang-Yang, Wu Zhi-Gang
机构信息
Department of Urology, The First Hospital Affiliated to Wenzhou Medical College, Wenzhou, Zhejiang 325000, China.
出版信息
Zhonghua Nan Ke Xue. 2011 Sep;17(9):842-6.
PMID:21961251
Abstract
Phosphodiesterase type 5 (PDE5) inhibitors are used most commonly in the treatment of penile erectile dysfunction (ED). Recent studies show that PDE5 inhibitors are ideal drugs for treating ischemia-reperfusion injury. This review focuses on the results of basic and clinical researches on PDE5 inhibitors for the treatment of ischemia-reperfusion injury and provides some theoretical evidence for clinical options of the drugs.
摘要
5型磷酸二酯酶（PDE5）抑制剂最常用于治疗阴茎勃起功能障碍（ED）。近期研究表明，PDE5抑制剂是治疗缺血再灌注损伤的理想药物。本文综述聚焦于PDE5抑制剂治疗缺血再灌注损伤的基础及临床研究结果，为该类药物的临床选择提供一些理论依据。
相似文献
1
[Update of PDE5 inhibitors for the treatment of ischemia-reperfusion].
Zhonghua Nan Ke Xue. 2011 Sep;17(9):842-6.
2
Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.
Expert Opin Pharmacother. 2010 May;11(7):1109-22. doi: 10.1517/14656561003698131.
3
[New application of phosphodiesterase-5 inhibitors in uro-andrology].
Zhonghua Nan Ke Xue. 2013 Aug;19(8):675-7.
4
[Update of PDE5 inhibitors as treatment of ED].
Zhonghua Nan Ke Xue. 2005 Jul;11(7):552-5.
5
Influence of erectile dysfunction course on its progress and efficacy of treatment with phosphodiesterase type 5 inhibitors.
Chin Med J (Engl). 2010 Nov;123(22):3258-61.
6
Alleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors.
Expert Opin Investig Drugs. 2011 Oct;20(10):1305-9. doi: 10.1517/13543784.2011.609315. Epub 2011 Aug 16.
7
PDE5 inhibitors: targeting erectile dysfunction in diabetics.
Curr Opin Pharmacol. 2011 Dec;11(6):683-8. doi: 10.1016/j.coph.2011.08.004. Epub 2011 Sep 15.
8
Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies.
Diabetes Metab. 2012 Feb;38(1):1-13. doi: 10.1016/j.diabet.2011.09.003. Epub 2011 Nov 4.
9
Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors.
Int J Clin Pract. 2007 Sep;61(9):1547-54. doi: 10.1111/j.1742-1241.2007.01482.x. Epub 2007 Jul 26.
10
Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Curr Med Res Opin. 2007 Dec;23(12):3189-98. doi: 10.1185/030079907X242656.
Zotero 插件